David Richardson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Richardson has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Karryn Brown
University of Cape Town
5 shared publications - Estelle Verburgh
Division of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
4 shared publications - Jenna Bailey
Division of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
3 shared publications - Katherine Antel
Medical University of South Carolina
3 shared publications - Dharshnee Rama Chetty
University of Cape Town
2 shared publications - Ellouise C. Adams
University of Cape Town
2 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1813
Early-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes
Background: Classic Hodgkin Lymphoma (cHL) is a highly curable cancer disproportionately affecting younger patients and those with human immunodeficiency virus (HIV) infection. In under-resourced regions with endemic HIV or tuberculosis, cHL treatment outcomes are poor when compared to high-income settings for numerous disease, patient and health systems related factors. Over 80% of patients present with advanced disease and reducing diagnosis delays is thought to be critical in improving survival. However, because early-stage cHL is relatively uncommon in these settings, data evaluating outcomes in patients with early-stage disease are lacking. Method: This retrospective study examined 70 patients with early-stage cHL. These patients, derived from a consecutive cohort of 387 cHL patients treated between 2010 and 2022, were meticulously staged with the Modified Lugano staging system and positron emission tomography / computed tomography (PET/CT). Progression-free survival (PFS), overall survival (OS), and the applicability of National Comprehensive Cancer Network (NCCN) risk stratification were assessed. Results: The median age at diagnosis was 35 years and most patients had stage II (86%), or unfavourable disease (76%). The 5-year OS for the favourable and unfavourable groups were similar (94% vs. 90%, P = 0.599) as was 5-year PFS (83% vs. 88%, P = 0.984). Five-year OS for the HIV positive patients was 94% and 90% in HIV negative patients ( P = 0.684), and PFS was 100% and 82%, respectively ( P = 0.086). Conclusions: This study demonstrated survival outcomes in early-stage cHL patients comparable with higher income countries, notwithstanding HIV status or unfavourable NCCN classification. In contrast to the previous study from our centre which showed overall survival rates of 66%, for patients with cHL of all disease stages, we highlight the importance of facilitating early diagnosis and treatment in low- and middle-income countries.
- 25 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1813
Open AccessEarly-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes
Background: Classic Hodgkin Lymphoma (cHL) is a highly curable cancer disproportionately affecting younger patients and those with human immunodeficiency virus (HIV) infection. In under-resourced regions with endemic HIV or tuberculosis, cHL treatment outcomes are poor when compared to high-income settings for numerous disease, patient and health systems related factors. Over 80% of patients present with advanced disease and reducing diagnosis delays is thought to be critical in improving survival. However, because early-stage cHL is relatively uncommon in these settings, data evaluating outcomes in patients with early-stage disease are lacking. Method: This retrospective study examined 70 patients with early-stage cHL. These patients, derived from a consecutive cohort of 387 cHL patients treated between 2010 and 2022, were meticulously staged with the Modified Lugano staging system and positron emission tomography / computed tomography (PET/CT). Progression-free survival (PFS), overall survival (OS), and the applicability of National Comprehensive Cancer Network (NCCN) risk stratification were assessed. Results: The median age at diagnosis was 35 years and most patients had stage II (86%), or unfavourable disease (76%). The 5-year OS for the favourable and unfavourable groups were similar (94% vs. 90%, P = 0.599) as was 5-year PFS (83% vs. 88%, P = 0.984). Five-year OS for the HIV positive patients was 94% and 90% in HIV negative patients ( P = 0.684), and PFS was 100% and 82%, respectively ( P = 0.086). Conclusions: This study demonstrated survival outcomes in early-stage cHL patients comparable with higher income countries, notwithstanding HIV status or unfavourable NCCN classification. In contrast to the previous study from our centre which showed overall survival rates of 66%, for patients with cHL of all disease stages, we highlight the importance of facilitating early diagnosis and treatment in low- and middle-income countries.
- Open Access
- 9 June 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 1
Corrigendum: Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
In the original published article, Adams EC, Antel K, Bailey JL, et al. Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region. S Afr J HIV Med. 2025;26(1):a1679. https://doi.org/10.4102/sajhivmed.v26i1.1679, the authors wish to also acknowledge the funder, the Cancer Association of South Africa (CANSA). Instead of: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345. It should be: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345 and the Cancer Association of South Africa (CANSA). The authors apologise for this error. The correction does not change the study’s findings of significance or overall interpretati
- 9 June 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 1
Open AccessCorrigendum: Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
In the original published article, Adams EC, Antel K, Bailey JL, et al. Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region. S Afr J HIV Med. 2025;26(1):a1679. https://doi.org/10.4102/sajhivmed.v26i1.1679, the authors wish to also acknowledge the funder, the Cancer Association of South Africa (CANSA). Instead of: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345. It should be: Funding information Research reported in this publication was supported by the Fogarty International Center and National Heart, Lung and Blood Institute of the National Institutes of Health under Award number D43 TW010345 and the Cancer Association of South Africa (CANSA). The authors apologise for this error. The correction does not change the study’s findings of significance or overall interpretati
- Open Access
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 8
The diagnostic pathway to lymph node excision biopsy in an HIV- and tuberculosis-endemic region
Background: In the HIV/tuberculosis endemic Western Cape public care setting, diagnostic consideration of patients with persistent lymphadenopathy focuses on extra-pulmonary tuberculosis (EPTB), delaying diagnosis of other infectious or malignant causes of lymphadenopathy. Objectives: To evaluate the diagnostic pathways of patients investigated for lymphadenopathy at Groote Schuur Hospital. Method: A retrospective review of patients undergoing lymph node excision biopsy was conducted to correlate test selection and results prior to biopsy with final patient diagnosis and assess the impact of pre-biopsy pathways on diagnostic delay. Results: Of 86 patients undergoing excision biopsy, 61 (71%) had no previous diagnosis to explain the lymphadenopathy. Extra-pulmonary tuberculosis was the commonest diagnosis (24.6%, 15/61), followed by lymphoma (21.3%, 13/61), and metastatic cancer (14.8%, 9/61). Median time from presentation with lymphadenopathy to first excision biopsy was 55 days (interquartile range [IQR] 22–106). Fine needle aspiration (FNA) cytology of lymphadenopathy was performed in 30 out of 61 (49%) of the patients and repeated in a third of these, while smear for acid-fast bacilli and culture for Mycobacterium tuberculosis were infrequently performed, and the GeneXpert MTB/RIF assay on FNA was never performed. FNA cytology was non-diagnostic in all seven patients with lymphoma in whom it was performed. Conclusion: In patients with lymphadenopathy, we demonstrate how poorly structured diagnostic pathways contribute to unnecessary healthcare utilisation and diagnostic delay in treatable conditions. Providing early access to biopsy after appropriate workup ensures accurate diagnosis of unexplained lymphadenopathy.
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 8
Open AccessThe diagnostic pathway to lymph node excision biopsy in an HIV- and tuberculosis-endemic region
Background: In the HIV/tuberculosis endemic Western Cape public care setting, diagnostic consideration of patients with persistent lymphadenopathy focuses on extra-pulmonary tuberculosis (EPTB), delaying diagnosis of other infectious or malignant causes of lymphadenopathy. Objectives: To evaluate the diagnostic pathways of patients investigated for lymphadenopathy at Groote Schuur Hospital. Method: A retrospective review of patients undergoing lymph node excision biopsy was conducted to correlate test selection and results prior to biopsy with final patient diagnosis and assess the impact of pre-biopsy pathways on diagnostic delay. Results: Of 86 patients undergoing excision biopsy, 61 (71%) had no previous diagnosis to explain the lymphadenopathy. Extra-pulmonary tuberculosis was the commonest diagnosis (24.6%, 15/61), followed by lymphoma (21.3%, 13/61), and metastatic cancer (14.8%, 9/61). Median time from presentation with lymphadenopathy to first excision biopsy was 55 days (interquartile range [IQR] 22–106). Fine needle aspiration (FNA) cytology of lymphadenopathy was performed in 30 out of 61 (49%) of the patients and repeated in a third of these, while smear for acid-fast bacilli and culture for Mycobacterium tuberculosis were infrequently performed, and the GeneXpert MTB/RIF assay on FNA was never performed. FNA cytology was non-diagnostic in all seven patients with lymphoma in whom it was performed. Conclusion: In patients with lymphadenopathy, we demonstrate how poorly structured diagnostic pathways contribute to unnecessary healthcare utilisation and diagnostic delay in treatable conditions. Providing early access to biopsy after appropriate workup ensures accurate diagnosis of unexplained lymphadenopathy.
- Open Access
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 7
Diagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
Background: Extrapulmonary tuberculosis (EPTB) is common among people living with HIV (PLWH). Abdominal ultrasound is an accessible investigation, frequently employed to support the diagnosis of EPTB, but may lead to misdiagnoses of diseases with overlapping clinical features, such as lymphoma. Objectives: To describe the abdominal ultrasound features and confirmed diagnoses of patients referred to a biopsy clinic with unexplained lymphadenopathy. Method: This was a retrospective descriptive study of patients attending the peripheral lymph node biopsy clinic at Groote Schuur Hospital between 2017 and 2020, who had abdominal ultrasound examinations while being investigated for unexplained lymphadenopathy. Ultrasound features were compared to the final diagnosis made on the lymph node biopsy. Results: Thirty-four patients were included, most of whom were PLWH (59%). Approximately one-third had a confirmed diagnosis of lymphoma (29%) and approximately one-third had a confirmed diagnosis of tuberculosis (32%). Splenic hypoechoic lesions were more common in patients with lymphoma (64%) than in patients with tuberculosis (46%) and malignancy (17%). Ascites was equally distributed between patients with tuberculosis (36%) and lymphoma (36%). The ultrasound report and confirmed diagnoses agreed in 40% of patients with tuberculosis. Additionally, 36% of patients with confirmed lymphoma were suspected to have tuberculosis based on the abdominal ultrasound. Conclusion: Abdominal ultrasound abnormalities such as splenic hypoechoic lesions, lymphadenopathy, and ascites/pleural effusion have a differential diagnosis including both tuberculosis and lymphoma, and should be investigated accordingly.
- 1 January 2025
- Published by AOSIS in Southern African Journal of HIV Medicine
- Vol. 26 (1) , 7
Open AccessDiagnostic use of abdominal ultrasound in detecting extrapulmonary tuberculosis or lymphoma in an HIV-endemic region
Background: Extrapulmonary tuberculosis (EPTB) is common among people living with HIV (PLWH). Abdominal ultrasound is an accessible investigation, frequently employed to support the diagnosis of EPTB, but may lead to misdiagnoses of diseases with overlapping clinical features, such as lymphoma. Objectives: To describe the abdominal ultrasound features and confirmed diagnoses of patients referred to a biopsy clinic with unexplained lymphadenopathy. Method: This was a retrospective descriptive study of patients attending the peripheral lymph node biopsy clinic at Groote Schuur Hospital between 2017 and 2020, who had abdominal ultrasound examinations while being investigated for unexplained lymphadenopathy. Ultrasound features were compared to the final diagnosis made on the lymph node biopsy. Results: Thirty-four patients were included, most of whom were PLWH (59%). Approximately one-third had a confirmed diagnosis of lymphoma (29%) and approximately one-third had a confirmed diagnosis of tuberculosis (32%). Splenic hypoechoic lesions were more common in patients with lymphoma (64%) than in patients with tuberculosis (46%) and malignancy (17%). Ascites was equally distributed between patients with tuberculosis (36%) and lymphoma (36%). The ultrasound report and confirmed diagnoses agreed in 40% of patients with tuberculosis. Additionally, 36% of patients with confirmed lymphoma were suspected to have tuberculosis based on the abdominal ultrasound. Conclusion: Abdominal ultrasound abnormalities such as splenic hypoechoic lesions, lymphadenopathy, and ascites/pleural effusion have a differential diagnosis including both tuberculosis and lymphoma, and should be investigated accordingly.
- Open Access
From the marrow to the blood: optimising the diagnosis of iron deficiency in the setting of inflammation